TPX2, TPX2 microtubule nucleation factor, 22974

N. diseases: 122; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE To elucidate the mechanism of TPX2 in suppressing cell invasion and migration medicated by miR-491in breast cancer, we further transfected TPX2 siRNAs into MCF-7 cells to delete endogenous TPX2, along with the transfections with miR-491 inhibitor into MCF-7 cell lines. 31799669 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.050 Biomarker disease BEFREE In short, all the results suggested that miR-491 functioned as a tumor suppressor by targeting TPX2 in BC and the miR-491 restoration may be an effective therapy for the BC treatment in the future. 31799669 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.040 Biomarker disease BEFREE In short, all the results suggested that miR-491 functioned as a tumor suppressor by targeting TPX2 in BC and the miR-491 restoration may be an effective therapy for the BC treatment in the future. 31799669 2019
CUI: C0029134
Disease: Optic Neuritis
Optic Neuritis 		0.020 Biomarker disease BEFREE The rates of change in the absence of optic neuritis (ON) for minimal VEP intervals of ≥3 months between baseline and last follow-up were +1.951 ms/y (n = 101 eyes; SD = 6.274; <i>p</i> = 0.012) for the P100 latencies and -2.149 µV/y (n = 64 eyes; SD = 5.013; <i>p</i> = 0.005) for the P100-N140 amplitudes. 31796527 2020
CUI: C0027873
Disease: Neuromyelitis Optica
Neuromyelitis Optica 		0.010 Biomarker disease BEFREE A total of 548 longitudinally assessed full-field visual evoked potentials (VEP) of 167 patients with NMOSD from 16 centers were retrospectively evaluated for changes of P100 latencies and P100-N140 amplitudes. 31796527 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.360 Biomarker disease BEFREE Totally, 427 upregulated (e.g., cell division cycle associated 5 [<i>CDCA5</i>], kinesin family member 4A [<i>KIF4A</i>], TPX2 microtubule nucleation factor [<i>TPX2</i>]) and 313 downregulated (e.g., metallothionein 1E [<i>MT1E</i>]) DEGs were identified in HCC. 31593490 2019
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 Biomarker disease BEFREE Novel molecules able to interfere with GOLPH3 and TPX2 pathways may have therapeutic benefits when used in combination with standard DNA damaging therapeutic agents in neuroblastoma. 31557970 2019
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.020 Biomarker disease BEFREE Novel molecules able to interfere with GOLPH3 and TPX2 pathways may have therapeutic benefits when used in combination with standard DNA damaging therapeutic agents in neuroblastoma. 31557970 2019
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.020 Biomarker disease BEFREE Novel molecules able to interfere with GOLPH3 and TPX2 pathways may have therapeutic benefits when used in combination with standard DNA damaging therapeutic agents in neuroblastoma. 31557970 2019
CUI: C3179349
Disease: Gastrointestinal Stromal Sarcoma
Gastrointestinal Stromal Sarcoma 		0.010 AlteredExpression disease BEFREE Additionally, we identified potential PI3K-related genes, the expression of which was upregulated (SNAI1 and TPX2) or downregulated (BANK1) in malignant GIST. 31553483 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.020 Biomarker disease BEFREE Using bioinformatic analysis, we revealed that TOP2A could be adopted as a prognostic indicator of NSCLC and it potentially regulate cancer development through co-work with TPX2. 31528121 2019
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.020 AlteredExpression disease BEFREE Our study demonstrated that an elevated TPX2 protein level was significantly associated with worse outcomes in the patients with TNBC, including worse progression-free survival (PFS) and overall survival (OS) (log-rank test, P < .001). 31494045 2019
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma 		0.020 AlteredExpression disease BEFREE Our study demonstrated that an elevated TPX2 protein level was significantly associated with worse outcomes in the patients with TNBC, including worse progression-free survival (PFS) and overall survival (OS) (log-rank test, P < .001). 31494045 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.020 Biomarker disease BEFREE Increased P100 amplitude and latency may reflect reduced amygdala volume and disruptions in the visual system, while decreased N170 and increased VPP amplitudes may reflect impaired perceptual processing, mitigated by a greater involvement of prefrontal areas for task performance in AD. 31401490 2019
CUI: C0023269
Disease: leiomyosarcoma
leiomyosarcoma 		0.010 AlteredExpression disease BEFREE CHI3L1, MELK, PRC1, TOP2A, and TPX2 were overexpressed in leiomyosarcomas, while HPGD and TES were overexpressed in leiomyomas. 31301306 2019
CUI: C0031485
Disease: Phenylketonurias
Phenylketonurias 		0.010 Biomarker group BEFREE The findings indicate that DHA supplementation in PKU patients from 2 weeks to 47 years of age improves DHA status and decreases visual evoked potential P100 wave latency in PKU children from 1 to 11 years old.Neurocognitive data are inconclusive. 31284588 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.070 Biomarker phenotype BEFREE CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis. 31272499 2019
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.020 Biomarker disease BEFREE In a multivariable regression model, age and P100 latency were significant parameters for affecting AA in patients with MS (<i>p</i> < .001 and <i>p</i> = .001). 31172825 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.020 AlteredExpression disease BEFREE Among them, four hub genes (CCNB1, KIF4A, TPX2, and TRIP13) were eventually identified by using five different methods (survival analysis, one-way analysis of variance, the Spearman correlation analysis, receiver operating characteristic curve, and expression value comparison), which were significantly correlated with the prognosis of BC. 30927274 2019
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.010 AlteredExpression disease BEFREE Among them, four hub genes (CCNB1, KIF4A, TPX2, and TRIP13) were eventually identified by using five different methods (survival analysis, one-way analysis of variance, the Spearman correlation analysis, receiver operating characteristic curve, and expression value comparison), which were significantly correlated with the prognosis of BC. 30927274 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.010 AlteredExpression disease BEFREE Among them, four hub genes (CCNB1, KIF4A, TPX2, and TRIP13) were eventually identified by using five different methods (survival analysis, one-way analysis of variance, the Spearman correlation analysis, receiver operating characteristic curve, and expression value comparison), which were significantly correlated with the prognosis of BC. 30927274 2019
CUI: C0079772
Disease: T-Cell Lymphoma
T-Cell Lymphoma 		0.010 AlteredExpression disease BEFREE AKR1E2, SPECC1 and TPX2 were expressed variably in HS and T-cell lymphoma biopsies, but also at high levels in critical tissues, including kidney, brain and marrow, diminishing their utility. 30854786 2019
CUI: C0334663
Disease: Histiocytic sarcoma
Histiocytic sarcoma 		0.010 AlteredExpression disease BEFREE AKR1E2, SPECC1 and TPX2 were expressed variably in HS and T-cell lymphoma biopsies, but also at high levels in critical tissues, including kidney, brain and marrow, diminishing their utility. 30854786 2019
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.020 AlteredExpression disease BEFREE CCNE1 and TPX2 were co-overexpressed in TNBCs. 30665374 2019
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma 		0.020 AlteredExpression disease BEFREE CCNE1 and TPX2 were co-overexpressed in TNBCs. 30665374 2019